{"id":8712,"date":"2023-04-11T06:17:57","date_gmt":"2023-04-11T06:17:57","guid":{"rendered":"https:\/\/cobrca.org\/?page_id=8712"},"modified":"2025-04-01T12:19:57","modified_gmt":"2025-04-01T12:19:57","slug":"supporters-and-exhibitors","status":"publish","type":"page","link":"https:\/\/cobrca.org\/cobrca2024\/supporters-and-exhibitors\/","title":{"rendered":"Supporters and Exhibitors"},"content":{"rendered":"

Supporters and Exhibitors<\/h3>\n

CoBrCa would like to thank the supporters. It is with the support of the industry that CoBrCa can continue in its mission to promote research and education and to disseminate new knowledge
\nClick on the logo to find out more about the company!<\/strong><\/p>\n

Platinum Supporters<\/span><\/strong><\/h3>\n\n\n\n
\"\"<\/a><\/strong><\/td>\n\"Lilly\"<\/a><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Gold Supporter<\/span><\/strong><\/h3>\n\n\n\n
\"endomag\"<\/a><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Silver Supporters<\/span><\/strong><\/h3>\n\n\n\n
\"\"<\/a><\/td>\n\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

Bronze Supporters<\/span><\/strong><\/h3>\n<\/div>\n

 <\/p>\n\n\n\n\n\n
\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
\"\"<\/a><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

 <\/p>\n

Exhibitors (Main Exhibition Area)<\/span><\/strong><\/h3>\n<\/div>\n\n\n\n\n\n\n\n\n\n
\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n\"endomag\"<\/a><\/td>\n<\/tr>\n
\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
\"Lilly\"<\/a><\/td>\n\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n\"\"<\/a><\/td>\n<\/tr>\n
\"\"<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
<\/div>\n
\n

Exhibitors (Poster Area)<\/span><\/strong><\/h3>\n\n\n\n
\"Home\"<\/a><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n
Veracyte<\/strong> is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, our exclusive license to a best-in-class diagnostics instrument (the nCounter Analysis System) positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California.
\nFor more information, please visit www.veracyte.com <\/a>and follow the company on Twitter (@veracyte).<\/div>\n<\/div>\n
\n
A leading provider of cancer screening and diagnostic tests, Exact Sciences<\/strong> gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Oncotype DX Breast Recurrence Score\u00ae test and the Cologuard\u00ae stool DNA-based colorectal cancer screening test1<\/sup>, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. We serve patients in more than 90 countries and our Oncotype DX\u00ae test is the most commonly used genomic assay in the NHS for adjuvant chemotherapy treatment decision-making.
\nTo learn more, please visit www.exactsciences.com\/uk<\/a> or our product website www.oncotypeiq.com\/en-gb<\/a>. You can reach our Customer Support Team at europeansupport@exactsciences.com<\/a> | 020 3031 8087.<\/p>\n
1.<\/sup> Not available in the UK<\/em><\/div>\n
\n
GC AESTHETICS\u00ae<\/strong>
\nThe QUALITY <\/strong>you Expect
\nThe OPTIONS<\/strong> you Need
\nThe PEACE OF MIND<\/strong> you Demand
\nGC Aesthetics\u00ae is an established global medical device company focused on Aesthetic, Revision and Reconstruction procedures<\/strong>. With more than 40 years of experience<\/strong>, surgeons and patients in more than 70 countries with systems in place to ensure the safety of our products through pre-clinical testing, clinical studies and excellent global post-market surveillance use GCA\u00ae.
\nGCA\u00ae is A Confident Choice for Life\u2122<\/strong> supported by a 10-year prospective and multi-centric clinical study and an average of 17 years of extended long-term high patient satisfaction data<\/strong>. We provide the most comprehensive implant portfolio in the industry with breast, face, body implants and skin expanders to give surgeons quality surgical options.
\nMuch more than a European manufacturer of high-quality implants<\/strong>, we are proud to support our surgeons and patients by integrating and developing solutions<\/strong> that are designed to support the best outcome for women\u00b4s breast enhancement journey.
\nA Confident Choice for Life\u2122<\/strong>
\nFor more information, please visit https:\/\/www.gcaesthetics.com\/<\/a><\/div>\n<\/div>\n
\n
At Endomag<\/strong>, we believe everyone deserves a better standard of cancer care \u2013 that\u2019s why we design our unique magnetic technologies with both the clinician and patient in mind. Many leading hospitals across the world use our solutions to help breast cancer patients avoid surgery when it isn\u2019t needed, and experience better outcomes when it is.
\nOur Magseed\u00ae marker is a tiny, non-radioactive seed, ideal for accurately marking tumours and lymph nodes, while the Magtrace\u00ae lymphatic tracer is the world\u2019s first, long-lasting, non-radioactive dual tracer for lymphatic mapping. Paired with the Sentimag\u00ae localisation platform, they have now been widely proven across over 100 clinical studies, featuring more than 20,000 patients.
\nThe Sentimag\u00ae platform has already helped 450,000+ women worldwide to access more precise and less invasive breast cancer treatment. Are you ready to join the magnetic revolution?
\nFor more information, please visit visit www.endomag.com<\/a><\/div>\n<\/div>\n
\n
About Gilead Sciences<\/strong>
\nGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
\nFor more information, please visit visit www.gilead.com<\/a><\/div>\n<\/div>\n
\n
Daiichi Sankyo UK <\/strong>and AstraZeneca UK<\/strong>: Combining collective expertise to push the boundaries of what is possible in cancer care. Our collaboration is based on a shared commitment to support patients.
\nThe CoBrCa Conference 2024 is supported by the pharmaceutical industry through sponsorship and the purchase of exhibition space. Sponsoring companies have no influence or involvement in the preparation of this event.
\nUK\/ADC\/07\/24\/0016 | July 2024<\/span><\/i><\/div>\n<\/div>\n
\n
Synapse Medical UK<\/strong> has solidified its position as the premier provider of Diagnostic Imaging services in both Ireland and the UK. With a widespread presence across these regions, our company boasts a team of dedicated employees, including a proficient group of Clinical Sales Specialists. Our commitment is steadfast when it comes to ensuring that our customers not only meet but exceed their expectations in terms of service. Synapse Medical UK are delighted to invite you to stand No: 24 to witness first hand, our new innovative diagnostic imaging products.
\nFor more information, please visit www.synapsemedical.ie\/<\/a><\/div>\n<\/div>\n
\n
Establishment Labs\u00ae Holdings Inc. <\/strong>(NASDAQ: ESTA) is a global medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants\u00ae, the centerpiece of the MotivaImagine\u00ae platform.
\nMotiva Implants\u00ae are produced at two FDA compliant state-of-the-art facilities in Costa Rica and currently sold in over 80 countries through exclusive distributors or the Company\u2019s direct salesforce. In March 2018, Establishment Labs\u00ae received approval for an investigational device exemption (IDE) from the FDA to initiate the Motiva Implants\u00ae clinical trial in the United State. After more than a decade on the market, from 2010 to 2023, and 3 million implants sold, Motiva Implants\u00ae have consistently reported rates of less than 1 % device-related complications leading to reoperation.
\nFor more information, please visit establishmentlabs.com\/<\/a><\/div>\n<\/div>\n
\n
Agendia<\/strong> is a leading provider of innovative solutions in precision oncology, specializing in early-stage breast cancer. They offer reliable biological insights for personalized treatment decisions, using advanced genomic assays like MammaPrint\u00ae and BluePrint\u00ae. These assays help clinicians quickly identify the most effective treatment plan, reducing the risks of over- and under-treatment.
\nFounded in 2003 in Amsterdam, Agendia is headquartered in Irvine, California, with a state-of-the-art laboratory. Led by world-renowned scientists and oncologists, Agendia is dedicated to advancing genomic insights through ongoing research. Notably, their FLEX Study is the world\u2019s largest Real-World Evidence-based Breast Cancer database, aiming to revolutionize precision in breast cancer management. With cutting-edge technology, research, and innovation, Agendia strives to shape the future of precision oncology and make a significant impact in the fight against breast cancer.
\nDisclaimer:
\n\u00a92024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.<\/em>
\nFor more information, please visit www.agendia.com\/<\/a><\/div>\n<\/div>\n
\n
At Solventum<\/strong>, we enable better, smarter, safer healthcare to improve lives. We\u2019re a new company with a long legacy of creating breakthrough solutions for our customers\u2019 toughest challenges. Rooted in a history of diverse expertise with over 70+ years of expertise, we are a leader in the advanced wound care market (based on data from BCC Research report) and estimate that our products treat more than 1.6 million hard-to-heal wounds annually.
\nOur solutions are designed to accelerate healing, prevent complications and lower the total cost of care. With industry-leading products, education and support, Solventum helps you improve patient outcomes \u2014 and lead the way in healthcare.<
\nFor more information, please visit www.solventum.com\/en-gb\/home\/medical\/<\/a>\/div><\/div>\n
\n
Founded in 1987, Merit Medical Systems, Inc.<\/strong> is a leading manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Our Merit Oncology is the new standard of care in wireless localization. We help healthcare providers achieve better patient outcomes through clinical and cost effective care and drive progress through innovation, knowledge sharing and the latest scientific research. The SCOUT\u00ae Radar Localization system has been clinically demonstrated to drive value and improve patient outcomes. SCOUT is proven to improve radiology workflow and significantly reduce OR delays. This can mean more successful surgeries, optimized breast conservation strategies, and enhanced outcomes for women.
\nFor more information, please visit www.merit.com\/merit-oncology<\/a><\/div>\n
\n
At Menarini Stemline<\/strong>, we are committed to developing a broad pipeline of innovative, transformative therapies in Oncology & Haematology and making a difference in cancer patients\u2019 lives. We invest in developing precision medicine through our pipeline of investigational drugs and partner with cancer experts and research institutions globally. Stemline is part of the Menarini Group, a leading international pharmaceutical and diagnostics company.
\nFor more information, please visit www.menarinistemline.co.uk\/<\/a><\/div>\n
\n
PreludeDx<\/strong> is the leading personalized breast cancer diagnostics company dedicated to improving outcomes for patients diagnosed with DCIS (Ductal Carcinoma in Situ). The company provides patients and physicians with evidence-based tools to improve patient outcomes and reduce the cost to the healthcare system by helping to ensure women are not over or under treated. For women diagnosed with DCIS, PreludeDx provides a patented molecular test (DCISionRT\u00ae) that predicts a woman\u2019s personal likelihood or risk of developing DCIS recurrence in 10 years and invasive breast cancer in 10 years with or without adjuvant radiation therapy after breast conserving surgery.
\nFor more information, please visit PreludeDx.com<\/a><\/div>\n
\n
APIS<\/strong> is leveraging systems biology and multi-OMICs biodata for validation and translation of biomarkers into clinical utility. Our breast oncology product portfolio is expanding: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon – the APIS PIK3CA Mutations Kit is a qPCR assay for detection of the 5 most prevalent mutations in the PIK3CA gene.
\nFor more information, please visit www.apisassay.com\/<\/a><\/div>\n
\n
We\u2019re Breast Cancer Now<\/strong>, the research and support charity. We\u2019re here for everyone with breast cancer.
\nAlongside funding life-saving research and provide information and support, we work closely with healthcare professionals to make sure everyone affected by breast cancer gets the best treatment and care, when they need it.
\nWhy? Because our vision is that by 2050, everyone diagnosed with breast cancer will live and be supported to live well. But to make that vision a reality, we need to act now.
\nFor more information, please visit Breast Cancer Now | The research and support charity<\/a><\/div>\n
\n
Lilly<\/strong> is a medicine company turning science into therapies to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are advancing new discoveries to address some of the world’s most significant health challenges: redefining diabetes and obesity care; advancing the fight against Alzheimer’s disease; providing options for debilitating immune system disorders; and transforming the management of difficult-to-treat cancers. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. everyone diagnosed with breast cancer will live and be supported to live well. But to make that vision a reality, we need to act now.
\nTo learn more, visit Lilly UK<\/a> or Eli Lilly and Company UK & Ireland: Overview | LinkedIn<\/a><\/div>\n
\n
At Novartis UK<\/strong>, our purpose is to reimagine medicine to improve and extend people\u2019s lives.
\nWe use innovative science and technology to address some of society\u2019s most challenging healthcare issues and we work together with the system to implement solutions that drive access for UK patients.
\nFrom research to delivery, we are a valued partner in the healthcare ecosystem, supporting in times of crisis and beyond, to build solutions that provide better care and access opportunities for every patient in the UK.
\nFor more information, please visit www.novartis.com\/uk-en\/<\/a><\/p>\n
\n
At Siemens Healthineers<\/strong>, we pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. As a leader in medical technology, we want to advance a world in which breakthroughs in healthcare create new possibilities with a minimal impact on our planet. By consistently bringing innovations to the market, we enable healthcare professionals to innovate personalised care, achieve operational excellence and transform the system of care.
\nFor more information, please visit www.siemens-healthineers.co.uk<\/a><\/div>\n
\n
At Roche UK<\/strong>, we focus our energy and investment in developing tests and treatments that change lives and give us more quality time with the people we love. And, together with others, we\u2019re solving healthcare\u2019s greatest challenges; helping to achieve better results by connecting early diagnosis to targeted treatment and ongoing support.
\nHealthcare matters to all of us. That\u2019s why we work hard to ensure that all our new medicines are made available to those who need them through the NHS – wherever they live, whatever their circumstances.
\nIn 2020, more than 820 million Roche diagnostic tests were used to confirm, rule out or manage health conditions and over 712,000 patients benefited from our medicines and diabetes monitoring and insulin delivery system. During this period, we contributed \u00a31.26 billion to the UK economy, supporting over 21,000 jobs.
\nProud of what we do, we\u2019re here because we care. In the UK we employ over 2,000 brilliant specialists who work together to transform the lives of patients and their loved ones.
\nThat\u2019s what makes us who we are. That\u2019s what makes us Roche UK<\/strong>.
\nFor more information, please visit www.roche.co.uk\/<\/a><\/div>\n
\n
Dilon Technologies\u00ae Inc.<\/strong>, is a commercial stage women\u2019s healthcare company which develops, manufactures, and sells innovative medical devices for detecting and assessing cancerous tumors, hemostasis, as well as portable video laryngoscopes while expanding its footprint across hospitals to broaden its offering into Biosurgery. Based in Newport News, Virginia, Dilon strives to improve the quality of care by providing a wide range of innovative medical device technology that benefits patients around the world. Dilon\u2019s portfolio includes HEMOBLAST\u00ae Bellows, the only combination powdered surgical hemostat that contains collagen, thrombin and chondroitin sulfate, MarginProbe\u00ae, a groundbreaking technology for accurate margin assessment in breast cancer surgery, the Navigator\u2122 2.0 and 3.0 gamma probe Systems, for radio-guided lymphatic mapping and tumor localization that is sterilizable and autoclavable, TrueView\u2122 Pro 100, a specimen radiography system (SRS) that uses advanced radiography and automated software to precisely identify tumor lesions in resected or biopsied breast tissue, and the CoPilot\u00ae, an innovative, portable, and easy to use video laryngoscope.
\nFor more information, please visit www.dilon.com<\/a><\/div>\n
\n
The Association of Breast Surgery<\/strong> was established in 2010 and is the voice for breast surgery in the UK. ABS members include surgeons, trainees, nurses and allied health professionals working as part of the Breast MDT. The ABS runs an annual conference and a number of courses and events throughout the year. It offers regular research grants and travel bursaries. Its Clinical Practice & Standards committee produces guidance for the use of UK healthcare professionals.
\nFor more information, please visit www.associationofbreastsurgery.org.uk<\/a>
\nFor more information, please visit www.dilon.com<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Supporters and Exhibitors CoBrCa would like to thank the supporters. It is with the support of the industry that CoBrCa can continue in its mission to [\u2026]<\/span><\/p>\n","protected":false},"author":12,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-8712","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/8712"}],"collection":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/comments?post=8712"}],"version-history":[{"count":104,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/8712\/revisions"}],"predecessor-version":[{"id":10377,"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/pages\/8712\/revisions\/10377"}],"wp:attachment":[{"href":"https:\/\/cobrca.org\/cobrca2024\/wp-json\/wp\/v2\/media?parent=8712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}